Business
INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants
SARASOTA, Fla., Nov. 9, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on
About this update from Invo Fertility, Inc.
[{"type":"text","content":"SARASOTA, Fla., Nov. 9, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) (\"INVO\" or the \"Company\"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide with its INVOcell® medical device and the intravaginal culture (\"IVC\") procedure it enables, announced that it is soliciting waivers (the \"Waiver Solicitation\") from holders of the Company's common stock purchase warrants dated August 8, 2023 (the \"Warrants\") of the holder's right to exercise a cash payment option upon consummation of the previously announced proposed merger with NAYA Biosciences, Inc., a Delaware corporation (\"NAYA\"). Receipt of the waivers is a condition to the consummation of the merger.\n\n \n \n \n \n \n \n\n \nThe Waiver Solicitation is being made pursuant to a notice of waiver solicitation (the \"Notice of Waiver Solicitation\") and accompanying form of waiver, which the Company is sending to the holders of the Warrants. The Notice of Waiver solicitation sets forth the terms of the Warrant Solicitation.\nThe Waiver Solicitation is scheduled to expire at 5:00 p.m., New York City time, on November 15, 2023. \nFurther details of the Waiver Solicitation are included in the Notice of Waiver Solicitation, which is to be furnished on a Form 8-K with the Securities and Exchange Commission and which will be available on the Company's website, www.invobio.com.\nThis press release does not constitute a solicitation of waivers of holders of the Warrants and shall not be deemed a solicitation of waivers with respect to any other securities of the Company. The Waiver Solicitation will be made solely by the Notice of Waiver Solicitation and the accompanying waiver form.\nImportant Additional Information will be filed with the SECThis communication is being made in respect of the proposed transaction between the Company and NAYA (the \"Proposed Transaction\"). In connection with the proposed transaction, the Company and NAYA will file relevant materials with the SEC, including a registration statement on Form S-4 to be filed by the Company that will include a proxy statement of the Company that also constitutes a prospectus of the Company. A definitive proxy statement/prospectus will be mailed to stockholders of the Company and of NAYA. \nThis communication is not a substitute for the registration statem...